ErVimmune is a startup based in France, most recent round Series A.
ErVimmune is a startup based in France. Its most recent tracked round is Series A.
ErVimmune is a French biotechnology company developing cancer vaccines and T cell-based therapies targeting shared non-conventional tumor antigens derived from human endogenous retroviruses to address unmet medical needs in cold tumors.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.